Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Manchester United PLC (MANU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Manchester United PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Manchester United PLC trades at $21.87 (market cap $3.85B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Manchester United PLC pays a 1.26% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MANU | |
|---|---|---|
Market Cap | $4.49B | $3.85B |
Sector | Health | Media |
52-Week High | $28.06 | $23.53 |
52-Week Low | $20.06 | $15.10 |
Enterprise Value | $3.69B | $4.77B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Manchester United (MANU) trades at $22.35, down 3.29% on the day, with a bullish technical outlook from moving averages but mixed oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, while revenue trends show modest growth to $667M in 2025. Recent news highlights stadium expansion plans and Champions League qualification as positive catalysts, though profitability remains challenged with a net income margin of -4.96% in 2025.
The outlook is cautiously optimistic with analyst consensus leaning hold (60%) amid valuation concerns (P/S 4.25, P/B 16.21). Key opportunities include revenue upside from new stadium and European competition, while risks involve persistent losses, high debt, and sports performance volatility. The stock's proximity to its 52-week high of $24.22 suggests limited near-term upside without fundamental improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
